FDA will miss rare decision deadline for Savara candidate after three-month delay
Savara shares dropped 18% on the news, though analysts remain confident in approval, instead pointing to potential “bandwidth issues” at the FDA.
Savara shares dropped 18% on the news, though analysts remain confident in approval, instead pointing to potential “bandwidth issues” at the FDA.
comments(0)
5-min edit window · permanent after that